viernes, 9 de febrero de 2018

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer February 7, 2018

U.S. Food and Drug Administration Header

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer

FDA approved abiraterone acetate (Zytiga, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). More Information.  February 7, 2018

Other Hematology/Oncology (Cancer) Approvals & Safety Notifications

No hay comentarios:

Publicar un comentario